Red Coral Pharmaceutical

Red Coral Pharmaceutical (Guangdong Red Coral Pharmaceutical Co., Ltd.) is a Chinese pharmaceutical company specializing in the research, development, manufacturing, and commercialization of modern traditional Chinese medicines (TCM), chemical drugs, and health supplements. Founded in 1998 and headquartered in Dongguan's Songshan Lake High-tech Industrial Development Zone, the company is a key subsidiary of the Red Coral Pharmaceutical Group. Its flagship commercial products include the Yiqi Weixue series (granules, tablets, and capsules), which are national exclusive patented products containing bio-organic heme iron extracted from pig blood, widely used for treating iron deficiency anemia. In its R&D pipeline, Red Coral is advancing modern drug delivery systems, notably its long-acting Pramipexole transdermal patch (PKA transdermal patch) for Parkinson's disease, which entered Phase 1 clinical trials in late 2025.